The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected …
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected …
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor …
An August 5 public meeting convened by the Reagan-Udall Foundation for the FDA examined how approved medicines could …
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully …
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare …
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they …
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, …
The Trump administration’s pick for Assistant Secretary for Preparedness and Response has a history of linking hepatitis B …
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
Already a subscriber? Log in